RNXT

RenovoRx, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website renovorx.com
Employees(FY) 10
ISIN US75989R1077

Performance

+8.66%

+19.0%

+12.26%

-13.14%

-48.03%

YTD

+95.4%

Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.

Advanced Technical Analysis

Technical Analysis of RNXT 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83, indicating robust upward momentum, while the Technical Score of 70 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of RNXT

Stock Rank

Recent News & Updates

2024-11-19 19:45
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial(Globenewswire)
2024-11-13 19:00
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights(Globenewswire)
2024-09-24 20:30
RenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians(Globenewswire)
2024-09-18 20:30
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP for Targeted Treatment of Locally Advanced Pancreatic Cancer(Globenewswire)
2024-08-26 20:30
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York(Globenewswire)
2024-08-14 00:13
RenovoRx continues drug-device combo Phase III trial in pancreatic cancer(Yahoo Finance)
2024-08-13 20:30
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial(Globenewswire)
2024-08-13 10:52
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024(Investorplace)
2024-07-30 20:30
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist(Globenewswire)
2024-07-07 20:30
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist(Globenewswire)
2024-06-25 20:30
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial(Globenewswire)
2024-06-09 20:30
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships(Globenewswire)
2024-05-29 20:30
RenovoRx CEO Issues Update Letter to Shareholders(Businesswire)
2024-05-20 21:00
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRxs TAMP Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery(Businesswire)
2024-05-13 21:00
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024(Businesswire)
2024-05-12 21:53
RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024(Investorplace)
2024-05-01 21:00
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024(Businesswire)
2024-04-17 20:30
RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement(Businesswire)
2024-04-15 20:30
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting(Businesswire)
2024-04-14 20:00
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026(Businesswire)
2024-04-08 01:52
RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023(Investorplace)
2024-04-07 20:30
RenovoRx Announces $11.1 Million at Market Private Placement(Businesswire)
2024-04-04 20:30
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024(Businesswire)
2024-03-11 21:00
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024(Businesswire)
2024-03-08 03:05
RenovoRx Highlights Key Leadership Promotions(Businesswire)
2024-02-05 19:30
RenovoRx CEO Issues Letter to Shareholders(Businesswire)
2024-01-28 19:30
RenovoRx Closes $6.1 Million Private Placement(Businesswire)
2023-12-20 19:30
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer(Businesswire)
2023-12-18 19:30
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting(Businesswire)
2023-12-12 19:31
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform(Businesswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.